Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 9:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 142 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Menopausal Osteoporosis Clear all
Completed No phase listed Observational

Circulating miRNA in Primary Hyperparathyroidism

NCT03931109
View directory record Official record
Conditions
Primary Hyperparathyroidism, Osteoporosis, Postmenopausal
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
50 Years to 100 Years · Female only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Jul 23, 2026, 9:00 PM EDT
Completed No phase listed Observational

Assessment of Cortical Bone Mechanics Technology (CBMT) Fracture Discrimination Capability

NCT05721898
View directory record Official record
Conditions
Osteoporosis, Osteopenia or Osteoporosis, Osteoporosis, Postmenopausal, Osteoporosis Risk, Osteoporotic Fractures, Fragility Fracture, Bone Fracture
Interventions
Cortical Bone Mechanics Technology
Diagnostic Test
Lead sponsor
Ohio University
Other
Eligibility
50 Years to 80 Years · Female only
Enrollment
394 participants
Timeline
2022 – 2023
U.S. locations
5
States / cities
Gainesville, Florida • Jacksonville, Florida • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Jul 23, 2026, 9:00 PM EDT
Completed Phase 3 Interventional Results available

A Double-blind Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis

NCT02157948
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
Denosumab (CP2), Denosumab (CP4)
Drug
Lead sponsor
Amgen
Industry
Eligibility
55 Years to 100 Years · Female only
Enrollment
394 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
10
States / cities
Santa Maria, California • South Lake Tahoe, California • Lakewood, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2017 · Synced Jul 23, 2026, 9:00 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Radius Loading in Primary Hyperparathyroidism

NCT01571843
View directory record Official record
Conditions
Primary Hyperparathyroidism, Bone Diseases, Metabolic, Osteoporosis, Postmenopausal, Bone Loss, Postmenopausal
Interventions
Forearm exercise program, Walking program
Other
Lead sponsor
Columbia University
Other
Eligibility
45 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2015 · Synced Jul 23, 2026, 9:00 PM EDT
Completed Phase 2 Interventional Results available

Denosumab, Teriparatide or Both for the Treatment of Postmenopausal Osteoporosis

NCT00926380
View directory record Official record
Conditions
Osteoporosis
Interventions
denosumab, teriparatide
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years and older · Female only
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 28, 2018 · Synced Jul 23, 2026, 9:00 PM EDT
Completed Phase 3 Interventional Results available

Study Investigating PK, PD, Efficacy, Safety, and Immunogenicity of Biosimilar Denosumab (GP2411) in Patients With Postmenopausal Osteoporosis

NCT03974100
View directory record Official record
Conditions
Postmenopausal Women With Osteoporosis
Interventions
GP2411, EU-Prolia (EU-authorized Prolia®)
Biological
Lead sponsor
Sandoz
Industry
Eligibility
55 Years to 80 Years · Female only
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
6
States / cities
Peoria, Arizona • Miami, Florida • Wichita, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Jul 23, 2026, 9:00 PM EDT
Completed Phase 3 Interventional Results available

Comparative Efficacy and Safety Study of RGB-14-P and Prolia® in Women With Postmenopausal Osteoporosis

NCT05087030
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
RGB-14-P, Prolia®
Drug
Lead sponsor
Gedeon Richter Plc.
Industry
Eligibility
60 Years to 90 Years · Female only
Enrollment
473 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Miami, Florida • Miami Lakes, Florida • Decatur, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Jul 23, 2026, 9:00 PM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Effect of Blueberries on Bone Turnover

NCT02630797
View directory record Official record
Conditions
Osteoporosis, Postmenopausal, Bone Loss, Age-related
Interventions
Blueberry Baseline, Blueberry Low, Blueberry Medium, Blueberry High
Dietary Supplement
Lead sponsor
Purdue University
Other
Eligibility
45 Years to 70 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated May 6, 2018 · Synced Jul 23, 2026, 9:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Multiple-Dose Study to Evaluate Skin Irritation and Sensitization of Teriparatide Administered Transdermally in Healthy Postmenopausal Women

NCT01250145
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
LY333334, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
Female only
Enrollment
251 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Daytona Beach, Florida • Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Oct 22, 2012 · Synced Jul 23, 2026, 9:00 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow

NCT00634608
View directory record Official record
Conditions
Allergic Rhinitis, Asthma, Back Pain, Benign Prostatic Hypertrophy, Bursitis, Depression, Anxiety, Diabetes Mellitus, Esophageal Reflux, HIV Infections, Hyperlipidemia, Hypertension, Insomnia, Irritable Bowel Syndrome, Obesity, Osteoporosis (Senile), Shoulder Pain, Sinusitis, Symptomatic Menopause, Urinary Incontinence, Urinary Tract Infection, Vaginitis
Interventions
Health Information Prescription
Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced Jul 23, 2026, 9:00 PM EDT
Completed Phase 3 Interventional Results available

A Study to Test if TVB-009P is Effective in Relieving Postmenopausal Osteoporosis

NCT04729621
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
TVB-009, Prolia®
Combination Product
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
60 Years to 90 Years · Female only
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
20
States / cities
Phoenix, Arizona • Tucson, Arizona • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Jul 23, 2026, 9:00 PM EDT
Completed Phase 4 Interventional Results available

A Study of Ibandronate (Boniva) to Evaluate Bone Turnover Markers in Women With Treatment-Naive Postmenopausal Osteoporosis

NCT02598934
View directory record Official record
Conditions
Post Menopausal Osteoporosis
Interventions
Ibandronate
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Female only
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
50
States / cities
Montgomery, Alabama • Chandler, Arizona • Peoria, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2016 · Synced Jul 23, 2026, 9:00 PM EDT
Terminated Phase 4 Interventional

Risedronate vs Raloxifene in Hormone Replacement Therapy Discontinuation

NCT00790101
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Risedronate, Raloxifene, Placebo
Drug · Other
Lead sponsor
Sanofi
Industry
Eligibility
Up to 65 Years · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 10, 2011 · Synced Jul 23, 2026, 9:00 PM EDT
Completed Phase 3 Interventional

Calcium Supplementation in Postmenopausal Women

NCT00172172
View directory record Official record
Conditions
Osteoporosis
Interventions
PTH/Calcium, PTH/placebo, placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
45 Years and older · Female only
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
17
States / cities
Rancho Cucamonga, California • Lake Worth, Florida • Coeur d'Alene, Idaho + 14 more
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Jul 23, 2026, 9:00 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Soy Isoflavones on Bone Mineral Density and Physical Performance Indices

NCT00661856
View directory record Official record
Conditions
Osteoporosis
Interventions
Soy protein
Dietary Supplement
Lead sponsor
Creighton University
Other
Eligibility
55 Years to 72 Years · Female only
Enrollment
203 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2004
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 20, 2008 · Synced Jul 23, 2026, 9:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Blackcurrants Modify Gut Microbiota and Reduce Osteoporosis and CVD Risk

NCT04431960
View directory record Official record
Conditions
Postmenopausal Osteoporosis, Gut Microbiota, Cardiovascular Diseases
Interventions
blackcurrant (BC) extract
Drug
Lead sponsor
University of Connecticut
Other
Eligibility
45 Years to 60 Years · Female only
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Jul 23, 2026, 9:00 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone

NCT04467983
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Denosumab Injection, Abaloparatide
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
45 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jul 23, 2026, 9:00 PM EDT
Completed Phase 4 Interventional

OPTAMISE: Clinical Effectiveness of Teriparatide After Alendronate or Risedronate Therapy in Osteoporotic Postmenopausal Women

NCT00130403
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
risedronate sodium
Drug
Lead sponsor
Sanofi
Industry
Eligibility
55 Years to 85 Years · Female only
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 10, 2011 · Synced Jul 23, 2026, 9:00 PM EDT
Completed Phase 3 Interventional

Switching Osteoporosis Patients Currently on Oral Bisphosphonate to Zoledronic Acid

NCT00097812
View directory record Official record
Conditions
Osteoporosis
Interventions
zoledronic acid
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
45 Years to 79 Years · Female only
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
12
States / cities
Santa Rosa, California • Lakewood, Colorado • Gainsville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2012 · Synced Jul 23, 2026, 9:00 PM EDT
Completed Phase 3 Interventional

Study Comparing Arzoxifene With Raloxifene in Women After Menopause With Osteoporosis

NCT00383422
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Arzoxifene, Raloxifene
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years to 75 Years · Female only
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
5
States / cities
Gainesville, Georgia • Urbandale, Iowa • Billings, Montana + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2010 · Synced Jul 23, 2026, 9:00 PM EDT
Completed Phase 3 Interventional Results available

A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis

NCT00541658
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
risedronate
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
50 Years and older · Female only
Enrollment
923 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
20
States / cities
Birmingham, Alabama • Oakland, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2013 · Synced Jul 23, 2026, 9:00 PM EDT
Completed Phase 2 Interventional Results available

Parathyroid Hormone (PTH) for Osteoporosis in Postmenopausal Women

NCT00086619
View directory record Official record
Conditions
Postmenopausal Osteoporosis, Osteoporosis
Interventions
synthetic hPTH 1-34
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
46 Years to 85 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 29, 2013 · Synced Jul 23, 2026, 9:00 PM EDT
Completed Phase 1 Interventional

A Study to Determine the Patient Preference Between Zosano Pharma Parathyroid Hormone (ZP-PTH) Patch and Forteo Pen

NCT02478879
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
ZP-PTH, FORTEO
Drug
Lead sponsor
Zosano Pharma Corporation
Industry
Eligibility
55 Years to 85 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Aug 22, 2016 · Synced Jul 23, 2026, 9:00 PM EDT
Withdrawn Phase 2 Interventional

Romosozumab Effects on Bone Density, Muscle Mass, and Spine Surgery Outcomes

NCT06973109
View directory record Official record
Conditions
Osteoporosis, Post-menopausal
Interventions
Romosozumab, Alendronate (Fosamax), Placebo Romosozumab, Placebo Alendronate
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
65 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 23, 2026, 9:00 PM EDT